Cat. No. 3875
Chemical Name: 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-
Biological ActivityOrally effective vanilloid receptor 1 (TRPV1 receptor) antagonist. Inhibits acid- and capsaicin-induced activation of rat TRPV1 receptors (IC50 values are 6.0 and 35 nM respectively). Displays analgesic properties in rat models of inflammatory and neuropathic pain. CNS penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Pomonis et al (2003) N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J.Pharmacol.Exp.Ther. 306 387. PMID: 12721336.
Valenzano et al (2003) N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties. J.Pharmacol.Exp.Ther. 306 377. PMID: 12721338.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BCTC from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BCTC, supplier, vanilloid, trpv1, antagonists, transient, receptors, potential, channels, Tocris Bioscience, TRPV Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent TRPV1 antagonistPF 05105679
Selective TRPM8 blockerM 084 hydrochloride
TRPC4/5 channel blocker; antidepressant and anxiolyticA 425619
Potent TRPV1 antagonist
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.